Schott Pharma stock holds near 52-week high as Xetra trading stays calm

Published on 09/11/2026 at 19:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Schott Pharma stock traded around EUR 23.15 on Xetra on September 11, 2026, close to its 52-week high of EUR 23.75 from late August 2026. Recent trading data show modest volume and a sideways move despite solid earnings expectations for 2026.

Pop-Art-Comic zeigt Techniker im Reinraum an Fertigspritzen-Karussell — SCHOTT Pharma (DE000A3ENQ51) inszeniert einen Pop-Art-Comic mit Techniker am Fertigspritzen-Karussell in einem sterilen Reinraum, Illustration mit AI erstellt.

Schott Pharma stock (ISIN DE000A3ENQ51) traded around EUR 23.15 on Xetra on September 11, 2026, keeping the shares close to their recent 52-week high and signaling steady investor interest in the specialty pharma supplier.

Stock trades sideways near recent high

According to finanzen.ch data from September 11, 2026, the Schott Pharma share was quoted at EUR 23.15 in Xetra trading at 09:28 a.m., after opening at EUR 23.30 and moving in a narrow intraday range between EUR 23.15 and EUR 23.30.

Price statistics from finanzen.net show that Xetra volume reached 19,047 shares on September 11, 2026, underscoring a moderate trading activity as the stock consolidates near its recent high.

Shares close to 52-week high and earnings expectations

Per the same finanzen.ch report, Schott Pharma reached a 52-week high of EUR 23.75 on August 28, 2026, meaning that the September 11, 2026 Xetra price of EUR 23.15 stands only EUR 0.60, or about 2.5 percent, below that peak.

Analyst consensus figures cited by finanzen.ch indicate that experts currently expect Schott Pharma to earn EUR 0.983 per share in fiscal year 2026, providing a fundamental backdrop for the share price development.

Price level and market context

From an investor perspective, the combination of a share price near a 52-week high and earnings expectations of EUR 0.983 per share for 2026 suggests that the market is pricing in continued growth in Schott Pharma’s business, while the sideways move on September 11, 2026 reflects a phase of consolidation after the late August high.